# Pharmaceutical regulation in Iraq, from medicine approval to post-marketing

Source: https://onco.cc/key-papers/paper-al-jumaili-pharmaceutical-regulation-iraq-emhj-2021/  
OnCo record `paper-al-jumaili-pharmaceutical-regulation-iraq-emhj-2021` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A WHO regional journal report, written with Iraqi Ministry of Health and WHO staff, describing how medicines are approved, priced, bought, tested and monitored in Iraq, and naming budget shortfalls and shortages of essential medicines among the main problems.

## Summary

Published as "Pharmaceutical regulations in Iraq: from medicine approval to postmarketing". The main source was the Iraq pharmaceutical country profile 2020, prepared by the Ministry of Health with WHO. The report describes the Directorate of Technical Affairs as the regulator, the National Committee for Drug Selection and the essential and comprehensive medicines lists, registration and fast-track registration, pricing rules, KIMADIA's public procurement, the National Centre for Drug Control and Research, the Iraqi Pharmacovigilance Centre and the separate regulation of medicines in the Kurdistan Region.

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: Eastern Mediterranean Health Journal
- Year: 2021
- DOI: 10.26719/emhj.21.025
- Authors: Al-Jumaili AA, Younus MM, Kannan YJA, Nooruldeen ZE, Al-Nuseirat A.
- Findings: Registered medicines rose from 2,500 in December 2018 to 4,665 in August 2020, after fast-track registration was introduced in February 2019.; Fast-track registration gives a medicine approved by the FDA, EMA or other named regulators a temporary registration and import licence within one month; the regular pathway takes about a year.; KIMADIA procured 60% of level 1 essential medicines in 2019, and an insufficient budget is named as a main reason for shortages.; The national essential medicines list held 1,105 medicines and vaccines on 23 June 2020, 554 of them at level 1.
- What it means: It is the clearest public description of the route a cancer medicine takes into Iraq and into public hospitals, written partly by the people who run that route.
- Caveats: Describes the system in 2020; rules may have changed since.; Based mainly on a country profile prepared by the Ministry of Health itself.

## Sources

- East Mediterr Health J 2021: https://doi.org/10.26719/emhj.21.025
- PubMed: https://pubmed.ncbi.nlm.nih.gov/34766327/

## Connected records

- institutions: [Directorate of Technical Affairs, Ministry of Health, Iraq (medicines regulator)](https://onco.cc/institutions/iraq-moh-technical-affairs/), [KIMADIA, State Company for Marketing Drugs and Medical Appliances (Iraq)](https://onco.cc/institutions/kimadia-iraq/), [Kurdistan Medical Control Agency (KMCA), Kurdistan Region of Iraq](https://onco.cc/institutions/kmca-kurdistan/)

---
JSON: https://onco.cc/api/v1/entities/paper-al-jumaili-pharmaceutical-regulation-iraq-emhj-2021.json